This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Onda, M. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Onda, M. Articles by Pastan, I.

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Authors' Affiliations: ¹ Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland and ² Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Requests for reprints: Ira Pastan, Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5106, Bethesda, MD 20892-4264. Phone: 301-496-4797; Fax: 301-402-1344; E-mail: pastani{at}mail.nih.gov.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Purpose: Mesothelin is a cell surface protein that is highly expressed in some malignant tumors, and is a promising target for immunotherapy. Recent data suggests that mesothelin is an adhesive protein and may have a role in the metastases of ovarian cancer. Although a few monoclonal antibodies (MAb) to mesothelin have been produced, they have limitations for the study of expression of native mesothelin because of their low affinity or reactivity only with denatured mesothelin protein. We have produced novel MAbs to mesothelin to help study mesothelin function and to develop improved diagnosis and immunotherapy of mesothelin-expressing tumors.

Experimental Design: Mesothelin-deficient mice were immunized with plasmid cDNA encoding mesothelin, and boosted with a mesothelin-rabbit IgG Fc fusion protein prior to cell fusion. Hybridomas were screened by an ELISA using plates coated with mesothelin-Fc protein.

Results: Seventeen hybridomas producing anti-mesothelin antibodies were established and shown to react with two epitopes on mesothelin. One group reacts with the same epitope as the low affinity antibody K1 that was originally used to identify mesothelin. The other is a new group that reacts with a new epitope. One antibody from each group was chosen for further study and shown to react strongly on ELISA, on immunohistochemistry, and by fluorescence-activated cell sorting on living cells.

Conclusion: Our two newly established MAbs, MN and MB, have different and useful properties compared with current antibodies used for the detection of mesothelin by immunohistochemistry, fluorescence-activated cell sorting, ELISA, and Western blotting.

Hellstrom and colleagues developed an ELISA-based assay to detect a protein in the blood they term soluble mesothelin–related protein (17). The exact relationship of this protein to mesothelin is currently not clear. Interestingly, soluble mesothelin–related protein is elevated in many patients with mesothelioma and some patients with ovarian cancer (18).

Research in the mesothelin area has been hampered by the lack of well-characterized, readily available antibodies that could be used for immunohistochemistry on fixed tissues, Western blotting, fluorescence-activated cell sorting (FACS) analysis of cells from patients, and ELISA to measure mesothelin in the blood and body fluids and other purposes. We describe here two new antibodies reacting with different epitopes on mesothelin that can be used for all these applications.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Generation of a mesothelin-Fc fusion protein by mammalian cells. The extracellular domain of the human mesothelin was expressed as a fusion protein with rabbit IgG Fc in HEK 293T cells. The DNA fragment encoding rabbit IgG Fc was amplified by PCR using the plasmid pB1-12,14 for the RFc (amino acids 96-323, Swissprot, kindly provided by Dr. Rose G. Mage, NIH, ref. 19) as the template and inserted between SfiI and SacII sites of pSecTag2 (Invitrogen, Carlsbad, CA). cDNA for the extracellular domain of mesothelin was inserted between the SacII and NotI to obtain the plasmid pOND-rFc-Meso. Primers used were as follows: Meso forward; 5'-AGA TAG AGT CCG CGG GGA GGT GAA GTG GAG AAG ACA GCC TGT-3', Meso reverse; 5'-TTG TAT AGC GGC CGC TCA TCC CCC CGA GAG GGC CTC TTG CAC-3'. The plasmid was transfected into 293T cells by LipofectAMINE reagent (Invitrogen). The mesothelin-Fc protein harvested from the culture supernatant and purified with Hi-trap protein A column (Amersham Biosciences Corp., Piscataway, NJ). The purified proteins were quantitated by Coomasie blue (Pierce, Rockford, IL) and checked on SDS-PAGE gel.

Generation of a mesothelin protein by Escherichia coli. The mesothelin gene (GenBank accession number AY743922) was cloned from the IMAGE cDNA clone ID 5209096 using PCR and put it into pMAL-p2X (NEB, Beverly, MA) which has a tobacco etch virus protease cleavage site. The resulting plasmid pMH103 encodes a fusion protein consisting of the malE signal sequence, malE and mesothelin. The malE gene encodes the maltose-binding protein. The fusion protein is directed to the periplasm of Escherichia coli. The secreted proteins were separated with recombinant tobacco etch virus (Invitrogen). The samples were applied to an amylase column for removal of maltose-binding protein. The purity of bacterial mesothelin was >95%.

Cells. The pancreatic cancer cell line Panc 3.014 was obtained from Dr. Elizabeth Jaffee (Johns Hopkins Medical Institute, Baltimore, MD; ref. 16). It was maintained in RPMI 1640 supplemented with 20% fetal bovine serum, 200 µmol/L L-glutamine, 50 units/mL penicillin, 100 µg/mL streptomycin, 1% nonessential amino acids, 1% sodium pyruvate, and 2 units/mL human insulin. The human mesothelioma cells NCI-H226 was obtained from Dr. Isaiah J. Fidler (The University of Texas MD Anderson Cancer Center, Houston, TX). It was maintained in modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, and 1% nonessential amino acids. The human ovarian carcinoma cell line A1847 and human cervical carcinoma cell line HeLa were grown in DMEM supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin.

Immunization. Female mesothelin-deficient mice (6-8 weeks old) were immunized four times with the pcDNA3CAK1-9 plasmid intradermally (50 µg in 50 µL PBS) with 2-week intervals, and one boost was given with the mesothelin-Fc i.p. (50 µg in 100 µL of PBS) before fusion (5). Spleens were harvested 84 to 90 hours after the last boost for cell fusion. All animals were maintained in accordance with institutional guidelines.

Cell fusion. Cell fusions of the splenocytes and the SP2/0 cells were carried out according to the standard fusion protocol (20). Fourteen days after fusion, the supernatants were harvested and screened for antibody production by ELISA. The selected hybridomas were grown in a CELLINE flask (INTEGRA Biosciences, Chur, Switzerland) and purified on a protein A column (Amersham Biosciences).

Screening by ELISA on mesothelin-Fc fusion protein. Screening of hybridomas was done by ELISA. Briefly, Nunc-Immuno plates (Nalge Nunc International, Rochester, NY) were coated with 2 µg/mL of mesothelin-Fc protein. Plates were incubated overnight at 4°C. Then plates were blocked in blocking buffer (PBS with 25% DMEM, 5% FCS, 25 mmol/L HEPES, 0.5% bovine serum albumin, and 0.1% Azide) for 30 minutes at room temperature, washed twice with washing buffer (PBS with 0.05% Tween 20), and incubated with 100 µL supernatant of hybridoma for 1 hour at room temperature. After washing, plates were incubated with a horseradish peroxidase–conjugated goat anti-mouse antibody diluted 1:2,000 in blocking buffer. Finally, plates were washed with washing buffer and 100 µL immunopure tetramethylbenzidine substrate solution (Pierce) was added to each well. The color was allowed to develop for 2 to 5 minutes at room temperature and the reaction stopped by the addition of 50 µL 2 N solution of sulfuric acid. The plates were read at OD 450 nm using an automated plate reader (Molecular Devices Corp., Sunnyvale, CA).

Anti-mesothelin MAbs as control. MAb K1 was isolated and purified in our laboratory as previously described (2, 21). MAb 5B2 was obtained from Novocastra Laboratories, Ltd. (Newcastle upon Tyne, United Kingdom).

Antibody quantification. For the determination of MAb concentration, Sandwich ELISA was used. Nunc-Immuno plates (Nalge Nunc International) were coated with 2 µg/mL of goat anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., Grove, PA) in PBS overnight 4°C. One hundred microliters of blocking buffer was added to each well and then incubated for 30 minutes. After washing, serial diluted samples were added. As a standard immunoglobulin, mouse immunoglobulin classes and subclasses (Zymed Laboratories Inc., San Francisco, CA) were added. After washing, the bound MAbs were detected by a 1-hour incubation with horseradish peroxidase–labeled goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) followed by tetramethylbenzidine substrate kit (Pierce). After adding 2 N-H₂SO₄ 50 µL, the plates were read at OD₄₅₀. A standard curve was fit with the four-parameter logistic curve-fitting method.

Surface plasmon resonance assay. The affinity of the MAbs to mesothelin-rFc was determined by surface plasmon resonance using BIACore (Biacore, Piscataway, NJ). Three hundred and fifty response units of mesothelin-rFc was immobilized onto the biosensor chip, CM5 (using the BIACore amine coupling kit). On and off rates of MAbs were measured in PBS by injecting 25 µg/mL of each MAb over the chip surface for 5 minutes and then allowing the bound material to dissociate for 5 minutes by flowing only the buffer solution over the chip. Binding kinetics were analyzed using BIAevalutation 2.1 software (22).

Flow cytometry. Cultured cells (2 x 10⁵) were dissociated with dissociation buffer (Sigma-Aldrich, St. Louis, MO). Each sample was washed twice in FACS buffer (PBS plus 5% fetal bovine serum, and 0.1% sodium azide). One hundred microliters of each hybridoma supernatant was added to the cells and incubated for 1 hour at 4°C. Cells were then washed twice with FACS buffer, resuspended in 100 µL of a secondary antibody (R-PE conjugated goat anti-mouse IgG diluted 1:100; Biosource, Camarillo, CA) and incubated for another hour at 4°C. Finally, cells were washed twice and analyzed on a FACSCalibur machine (Becton Dickinson, Franklin Drive, NJ) using the CellQuest software.

Isotyping. The isotype of selected MAbs was determined using a mouse immunoglobulin isotyping kit (Roche Applied Science, Indianapolis, IN).

Western blot. Reactivity of anti-mesothelin MAbs to SDS-denatured antigen was tested in a Western blot analysis. Mesothelin-Fc and CD25-Fc were separated on 4% to 20% SDS polyacrylamide gels (Bio-Rad, Hercules, CA) under reducing conditions. Proteins were transferred to a 0.2 µm Immun-blot polyvinylidene difluoride membrane (Bio-Rad) in transfer buffer [25 mmol/L Tris-HCl, 192 mmol/L glycine, 30% (v/v) methanol (pH 8.3)] at 4°C for 1 hour at 240 mA. After blocking with blocking solution (Roche Applied Science), the membrane was incubated with 1 µg/mL of each MAb for 1 hour at room temperature. The bound MAbs were detected with alkaline phosphatase–labeled goat anti-mouse IgG (Biosource) and BDIP/nitroblue tetrazolium substrate (Pierce).

Immunohistochemistry. Archival paraffin-embedded formaldehyde-fixed tissue sections from patients with mesothelioma were evaluated for mesothelin expression (15). The sections were deparaffinized in xylene, followed by graded ethanol hydration into water. The sections were treated for antigen-retrieval either using: (a) a commonly used commercial antigen unmasking solution (Vector, Burlingame, CA); (b) citraconic anhydride in a boiling water bath at 97°C for 60 minutes (23); or (c) treatment with 3 mol/L urea in a boiling water bath for 60 minutes. These treatments were followed by blocking with 1% bovine serum albumin in PBS for 30 minutes at 23°C, then incubation with primary antibodies in 1% bovine serum albumin–PBS for 60 minutes at room temperature. Primary mouse antibodies 5B2 (Novocastra Laboratories), MAb K1, MAb MB, or MAb MN were used at (or at a preparation dilution equivalent to) 10 µg/mL. After washing in PBS, the sections were incubated with affinity-purified goat anti-mouse IgG conjugated to horseradish peroxidase (Jackson ImmunoResearch) at 25 µg/mL in 1% bovine serum albumin–PBS for 30 minutes, followed by detection of peroxidase with diaminobenzidine-peroxide substrate solution for 10 minutes at 23°C. The sections were counterstained with hematoxylin.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Generation of a recombinant mesothelin-Fc fusion protein and generation of MAbs. To obtain MAbs that recognize the extracellular domain of mesothelin, we used a DNA immunization protocol followed by protein immunization for the final boost prior to cell fusion (24). The mesothelin-Fc protein used for immunization and screening was prepared from the medium of transfected HEK293T cells by purification on protein A-Sepharose (22). Six mesothelin-deficient mice were injected intradermally with DNA prepared from the plasmid, pcDNA3CAK1-9. Blood was collected from the mice after multiple injections and the antibody titer was determined by ELISA on plates coated with mesothelin-Fc protein (data not shown). The two mice with the highest titer (>10⁵) were sacrificed. Spleen cells from each mouse were fused to myeloma cells following standard procedures (20). Supernatants from clones of hybridoma cells were screened using ELISA. To determine the specificity of the antibodies, the screening was done on plates coated with mesothelin-Fc and CD25-Fc. The latter is a negative control that excludes antibodies reacting with the Fc portion of the fusion. Finally, 17 hybridomas were identified that reacted selectively with mesothelin-Fc and not with CD25-Fc. The topographical epitopes of these MAbs were identified based on the mutual competition of all possible pairs of the MAbs (25). Two topographical epitope groups were identified. One group had 2 clones and contained MAb MB, whereas the other group had 15 clones and contained MAb MN, which competes with and belongs to the same epitope group as MAb K1. The characteristics of the two new MAbs and the two standard anti-mesothelin MAbs, K1 and 5B2, are shown in Table 1. The affinities of the new anti-mesothelin MAbs determined by BIACore (K_ds of 1.0 and 0.6 nmol/L) are much higher than previous MAbs. Because the new MAbs have high affinities for native mesothelin in the BIACore format, we examined their performance in other types of assays. In these studies, we compared them with the two commercially available antibodies and found them to be useful in all the assays for mesothelin, whereas the two others did not detect mesothelin in all assay conditions. The data is shown below and summarized in Table 1.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. FACS analysis of anti-mesothelin MAbs with different cells. Cells were incubated with the anti-mesothelin MAbs (1 µg/mL) or anti-CD30 MAbs, T6, as a negative control, followed by PE-labeled goat anti-mouse IgG. Each histogram shows the staining with first antibody (red line) and without first antibody (gray shadow). First antibody and cells used are shown. Mean fluorescence intensities for Table 1 were measured under the same conditions for all experiments.

View larger version (50K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Western blot analysis of anti-mesothelin MAbs. Mesothelin-Fc (lane 1, 100 ng; lane 2, 25 ng; lane 3, 6 ng; lane 4, 2 ng; and lane 5, 0.4 ng) and CD25-Fc (lane 6, 50 ng) were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were probed with each anti-mesothelin MAbs (1 µg/mL) or anti-CD30 MAb, T6 (control), followed by ALP-goat anti-mouse IgG and BCIP/nitroblue tetrazolium substrate. Each experiment was done under the same conditions. Data are summarized in Table 1.

ELISA. To assess the reactivity of the MAbs in an ELISA format, plates coated with 2 µg/mL of mesothelin-Fc were exposed to increasing concentrations of each of the MAbs. Figure 2A shows representative data from triplicate experiments. MAb MN showed the strongest signal followed by MAb MB. MAbs K1 and 5B2 showed a very weak signal. In a control ELISA using plates coated with CD25-Fc, none of the antibodies showed a signal (data not shown). Thus, MAb MN seems to be the best choice for detection of mesothelin in this ELISA format. In another ELISA format, plates were coated with mesothelin produced in E. coli and the reactivity of the antibodies compared. Figure 2B shows representative data from triplicate experiments. MN showed a very strong signal followed by 5B2, which showed a weak signal; K1 and MB, showed a very weak signal.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. MAb reactivity on ELISA coated with mesothelin-Fc (A), or bacterial maltose-binding protein–mesothelin (B). ELISA plates were coated with mesothelin-Fc (2 µg/mL) or bacterial mesothelin (2 µg/mL). Then, ELISA plates were incubated with anti-mesothelin MAbs, MN (), MB (), K1 (), or 5B2 (), followed by horseradish peroxidase–conjugated goat anti-mouse IgG. Experiments were done in triplicate. Points, mean; bars, ± SD (n = 3).

Immunohistochemistry. The patterns seen using peroxidase immunohistochemistry with different anti-mesothelin antibodies in the same area of the same case of mesothelioma are shown in Fig. 4. In (A), sections treated with a commercial antigen retrieval reagent (Vector) show very poor reaction with a case of mesothelioma using MAb K1, whereas (A') shows the result following antigen retrieval using 3 mol/L urea. The levels of reactivities detected under these conditions are comparable to those seen in the detection of mesothelin using MAb K1 in frozen sections (data not shown). Thus, MAb K1 can detect mesothelin expression, but only in frozen sections or paraffin sections treated using aggressive antigen retrieval, and is much less effective using more common commercial antigen retrieval reagents. As described below, a new aggressive antigen retrieval method using citraconic anhydride also improved K1 reactivity. On the other hand, MAb 5B2, a commercial antibody from Novocastra Laboratories, shows good reactivity after commercial antigen retrieval (B), a level of intensity similar to MAb MN shown in (D). MAb MB, however, shows superior reactivity with commercial antigen retrieval, as shown in (C). This pattern was observed in three separate cases of mesothelioma examined using these reagents. This suggests that MAb MB may be a superior reagent for use with commonly used commercial immunohistochemical procedures in archival paraffin-embedded tissues. We also showed that our newly established MAbs are specific for mesothelin-expressing cells using tissue arrays with different cancers and normal controls (Fig. 5; Table 2). These latter comparisons were made using citraconic anhydride antigen retrieval, a recently introduced reagent for antigen retrieval that is effective for epitopes that are difficult to unmask, including the K1-reactive epitope (ref. 23; data not shown).

View larger version (94K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. Immunohistochemistry of anti-mesothelin MAbs. Peroxidase immunohistochemical results are shown from the same area of the same case of mesothelioma. Formaldehyde-fixed, paraffin-embedded tissue sections were treated with a commercial antigen retrieval procedure (Vector; A-D), but one section was treated with the 3 mol/L urea antigen retrieval (A'). Anti-mesothelin primary antibodies were used to label these sections as follows: A and A', MAb K1; B, MAb 5B2; C, MAb MB; and D, MAb MN. Note that MAb K1 labels poorly with commercial antigen retrieval, but is much stronger using the 3 mol/L urea treatment, whereas the other antibodies label well using commercial antigen retrieval, with MAb MB (C) showing the most intense reaction (magnification, x200; bar, 50 µm).

View larger version (99K): [in this window] [in a new window] [Download PPT slide]   Fig. 5. Immunohistochemistry of anti-mesothelin MAbs on tissue arrays. Representative peroxidase immunohistochemical results are shown. Paraffin-embedded tissue sections (as shown in Table 2) were obtained from Biochain Institute (Hayward, CA) and treated with a citraconic anhydride antigen retrieval procedure (23). The complete results including other tissues are summarized in Table 2 (bar, 43 µm).

	Discussion

Top Abstract Materials and Methods Results Discussion References

For immunization, we used mesothelin-deficient mice, because they should not be tolerant to epitopes on human mesothelin that are also present in mouse mesothelin and therefore should react to more epitopes on mesothelin than normal mice (5). Using a mutual competition assay, we evaluated the epitopes recognized by the 17 new clones as well as those recognized by MAb K1 and immunotoxin SS1P (data not shown). We found that we obtained antibodies against only two epitopes. One of these epitopes was recognized by the K1 antibody previously made in normal mice. MAbs MN, K1 and immunotoxin SS1P, in which the Fv was obtained from an antibody phage library are in the same epitope group. MAb K1 was generated by immunization with the human ovarian cancer cell line OVCAR-3 (1, 2). On the other hand, the Fv of SS1P was cloned from the splenic mRNA of mice using antibody phage display. The mice were immunized with an expression vector coding for mesothelin. Fifteen of the 17 newly established MAbs reacted with this epitope. Because such antibodies are frequently generated by three different methods of immunization, this must be a dominant epitope (1, 11). MAb MN reacts with mesothelin-Fc protein and with mesothelin made in E. coli, showing that this epitope is present on recombinant mesothelin made in mammalian cells and in bacteria (Fig. 2). The epitope recognized by MAb MB does not react with mesothelin made in bacteria (Fig. 2B). MAb MB works very well for immunohistochemistry using a commercial antigen retrieval reagent (Vector) and should therefore be useful for such studies. On the other hand, even though it works for immunohistochemistry with commercial antigen retrieval methods, 5B2 reacts with the bacterial form of mesothelin, but not with the native mesothelin made in human cells.

The affinities of the new anti-mesothelin MAbs were measured by BIACore and found to have high affinities with K_ds of 1.0 and 0.6 nmol/L. These antibodies showed good performance when used for FACS analysis, ELISA, Western blot, and immunohistochemistry (Table 1). Thus, these MAbs are useful for detecting the mesothelin protein using all types of immunologic assays. Several studies have described the usefulness of detecting tumor mesothelin expression by immunohistochemistry as an aid in the pathologic diagnosis of mesothelioma, ovarian cancer, and pancreatic cancer. Although initial studies using MAb K1 on frozen sections suggested that mesothelin could help distinguish between mesothelioma and adenocarcinoma, a recent study using MAb 5B2 noted diffuse mesothelin expression in some lung adenocarcinomas (1, 10). Because mesothelin immunostaining is a very sensitive marker for epithelial mesothelioma, a negative mesothelin immunostain suggests a diagnosis other than mesothelioma (9). Tumor mesothelin expression has also been shown to be useful for the diagnosis of ovarian cancer. A study that looked at mesothelin expression by a variety of different tumors showed strong mesothelin expression by nonmucinous ovarian cancers but not in a variety of tumors with which these lesions may be confused; therefore, mesothelin staining can assist in establishing the differential diagnosis (10). Mesothelin expression in the majority of pancreatic ductal adenocarcinomas makes it a valuable tool for diagnosis of these tumors (3). In a study by Hornick et al., mesothelin in combination with other tumor markers was useful in distinguishing metastatic pancreatic adenocarcinoma from bile duct adenomas and hamartomas of the liver that are at times difficult to diagnose by light microscopy alone (26). Also, mesothelin immunostaining was shown to be valuable in distinguishing metastatic pancreatic mucinous adenocarcinomas in the ovaries from primary ovarian mucinous neoplasm; this is critical for proper patient management (27). Mesothelin staining can also help in the interpretation of pancreatic fine-needle aspiration given the cytologic overlap of neoplastic and reactive processes (28).

Hellstrom et al. have identified a soluble member of the mesothelin/MPF family, called soluble mesothelin–related protein that is elevated in the serum of the majority of patients with ovarian cancer (17). A recent study that evaluated serum CA 125 and soluble mesothelin–related protein in ovarian cancer patients and normal risk controls showed that using both markers together may be superior to CA 125 alone for ovarian cancer screening and diagnosis (29). In addition, soluble mesothelin–related protein has been shown to be a useful marker for the diagnosis of pleural mesothelioma and to follow disease progression (18). We have evidence that a small amount of cell-bound mesothelin is shed into the serum; this could be a valuable test for the diagnosis and follow-up of patients with mesothelin-expressing cancers.³

The detection of mesothelin expression by immunohistochemistry, besides being useful to the pathologists in making a diagnosis, is also important clinically to select patients for therapies targeting mesothelin (8) and the development of assays to measure serum mesothelin would be useful for the diagnosis and follow-up of patients with mesothelin-expressing cancers.

In conclusion, we have established new MAbs that react with mesothelin. Two of these, MN and MB, have better overall performance characteristics than previous MAbs and should be useful in studying the biology of mesothelin and also aid in the diagnosis and therapy of mesothelin-expressing cancers.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ Our unpublished data.

Received 3/15/05; revised 5/10/05; accepted 5/26/05.

	References

Top Abstract Materials and Methods Results Discussion References

 

1. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259–68.[Medline]
2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373–81.[Medline]
3. Argani P, Iacobuzio-Danahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862–8.[Abstract/Free Full Text]
4. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesothelioma, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136–40.[Abstract/Free Full Text]
5. Bera TK, Pastan I. Mesothelin is not required for normal mouse development on reproduction. Mol Cell Biol 2000;20:2902–6.[Abstract/Free Full Text]
6. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190–8.[Abstract/Free Full Text]
7. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. In press 2005.
8. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937–42.[Abstract/Free Full Text]
9. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mol Pathol 2003;16:192–7.
10. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418–28.[Medline]
11. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241–7.[Abstract/Free Full Text]
12. Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant anti-mesothelin immunotoxins against human gynecologic cancers grown in organotypic cultures in vitro. Clin Cancer Res 2002;8:3520–6.[Abstract/Free Full Text]
13. Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001;61:5070–7.[Abstract/Free Full Text]
14. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669–74.[Abstract/Free Full Text]
15. Hassan R, Kreitman RJ, Strauss L, et al. SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I and pharmacokinetic study of alternative-day infusion. Proc Am Soc Clin Oncol 2002;21:29a.
16. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8+ T cell response provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297–306.[Abstract/Free Full Text]
17. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531–6.[Abstract/Free Full Text]
18. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family protein and diagnosis of mesothelioma. Lancet 2003;362:1612–6.[CrossRef][Medline]
19. Bernstein KE, Alexander CB, Mage RG. Nucleotide sequence of a rabbit IgG heavy chain from the recombinant F-I haplotype. Immunogenetics 1983;18:387–97.[Medline]
20. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Monoclonal antibodies. Mol Pathol 2000;53:111–7.[Abstract/Free Full Text]
21. Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, Pastan I. 111-Indium-labelled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 1999;80:559–63.[CrossRef][Medline]
22. Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 2002;8:2345–55.[Abstract/Free Full Text]
23. Namimatsu S, Ghazizadeh M, Sugisaki Y. Reversing the effect of formalin fixation with citraconic anhydride and heat: a universal antigen retrieval method. J Histochem Cytochem 2005;53:3–11.[Abstract/Free Full Text]
24. Chowdhury PS, Pastan I. Analysis of cloned Fvs from a phage display library indicates that DNA immunization mimic antibody response generated by cell immunizations. J Immunol Methods 1999;231:83–91.[Medline]
25. Nagata S, Numata Y, Onda M, et al. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. J Immunol Methods 2004;292:141–55.[CrossRef][Medline]
26. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 2005;29:381–9.[CrossRef][Medline]
27. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 2005;24:67–72.[Medline]
28. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11:238–43.[Medline]
29. McIntosh MW, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9–15.[CrossRef][Medline]

This article has been cited by other articles:

				T. Fukazawa, J. Matsuoka, Y. Naomoto, Y. Maeda, M. L. Durbin, and N. Tanaka Malignant Pleural Mesothelioma-Targeted CREBBP/EP300 Inhibitory Protein 1 Promoter System for Gene Therapy and Virotherapy Cancer Res., September 1, 2008; 68(17): 7120 - 7129. [Abstract] [Full Text] [PDF]

				M. Onda, R. Beers, L. Xiang, S. Nagata, Q.-c. Wang, and I. Pastan An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes PNAS, August 12, 2008; 105(32): 11311 - 11316. [Abstract] [Full Text] [PDF]

				M. D. Johnson, F. Vito, and M. J. O'Connell Mesothelin Expression in the Leptomeninges and Meningiomas J. Histochem. Cytochem., June 1, 2008; 56(6): 579 - 585. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]

				T. Hucl, J. R. Brody, E. Gallmeier, C. A. Iacobuzio-Donahue, I. K. Farrance, and S. E. Kern High Cancer-Specific Expression of Mesothelin (MSLN) Is Attributable to an Upstream Enhancer Containing a Transcription Enhancer Factor Dependent MCAT Motif Cancer Res., October 1, 2007; 67(19): 9055 - 9065. [Abstract] [Full Text] [PDF]

				M. Ho, T. K. Bera, M. C. Willingham, M. Onda, R. Hassan, D. FitzGerald, and I. Pastan Mesothelin Expression in Human Lung Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1571 - 1575. [Abstract] [Full Text] [PDF]

				M. Onda, S. Nagata, M. Ho, T. K. Bera, R. Hassan, R. H. Alexander, and I. Pastan Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res., July 15, 2006; 12(14): 4225 - 4231. [Abstract] [Full Text] [PDF]

				D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al. Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2006; 12(8): 2434 - 2441. [Abstract] [Full Text] [PDF]

				R. Hassan, A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpank, R. Alexander, M. Willingham, I. Pastan, and M. Onda Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer Clin. Cancer Res., January 15, 2006; 12(2): 447 - 453. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Onda, M. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Onda, M. Articles by Pastan, I.